Metformin Cost in Pennsylvania 2026: Cash Price, Insurance, Medicaid, and Compounded Options

What Does Metformin Actually Cost in Pennsylvania in 2026?

Generic metformin is one of the most affordable prescription drugs available in Pennsylvania. At retail pharmacies across the state, cash-pay prices average around $8 per month for a standard 500 mg or 1 to 000 mg twice-daily regimen in 2026. That figure sits far below the manufacturer list price of approximately $40 per month.

The gap between list price and street price exists because metformin has been off-patent for decades. Dozens of generic manufacturers compete for the same market, which drives retail prices down to commodity levels. A 90-day supply (90 tablets of 1 to 000 mg) costs between $10 and $25 at most Pennsylvania Walmart, Kroger, Giant, and Rite Aid locations, depending on whether you use a savings card or a pharmacy's own generic program.

Why Prices Vary Across Pennsylvania Pharmacies

Not every pharmacy charges the same amount. Independent pharmacies in rural areas of the state, such as those serving Bradford or Cameron counties, may price 30-day supplies slightly higher, sometimes $12 to $15, simply because their volume is lower. Large-chain pharmacies in Philadelphia and Pittsburgh suburbs tend to offer the deepest discounts through internal generic programs.

GoodRx and similar third-party discount platforms can push the cash price below $5 at certain Pennsylvania CVS and Walgreens locations. The GoodRx pricing database has been studied in peer-reviewed literature; one 2022 analysis found third-party discount cards reduced out-of-pocket costs for common generics by 40 to 70 percent relative to the retail cash price before discounts [1].

Metformin extended-release (ER) formulations carry slightly higher prices, typically $10 to $18 per month cash-pay in Pennsylvania, because fewer generic manufacturers produce them and demand is lower than for immediate-release tablets.

Does Pennsylvania Medicaid (Medical Assistance) Cover Metformin?

Pennsylvania Medicaid, administered under the PA Department of Human Services and branded as Medical Assistance (MA), covers metformin for both type 2 diabetes and prediabetes without a prior authorization requirement as of 2026.

Pennsylvania's fee-for-service MA program and all five managed care organizations (Amerihealth Caritas, UPMC Health Plan, Geisinger Health Plan, Gateway Health, and Keystone First) list metformin on their formularies at the lowest cost-sharing tier, meaning most enrollees pay $0 to $3 per 30-day fill. The PA Department of Human Services drug formulary is publicly posted and updated quarterly.

Prediabetes Coverage Under PA Medicaid

Covering metformin for prediabetes is not universal across all state Medicaid programs, so Pennsylvania's policy is notable. The American Diabetes Association 2024 Standards of Care state: "Metformin should be considered in those with prediabetes, especially those with BMI <35 kg/m² aged <60 years who have had gestational diabetes" [2]. Pennsylvania Medicaid aligns with this guidance.

The landmark Diabetes Prevention Program (DPP) trial (N=3,234) found metformin 850 mg twice daily reduced the incidence of type 2 diabetes by 31% over 2.8 years compared with placebo (P<0.001) [3]. That evidence base is part of why PA Medicaid extended coverage beyond a strict type 2 diabetes diagnosis.

Is Compounded Metformin Legal in Pennsylvania?

Compounded metformin is legal in Pennsylvania when dispensed by a licensed 503A compounding pharmacy operating under state Board of Pharmacy oversight and federal USP standards.

A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed prescriber. In Pennsylvania, roughly 180 licensed 503A pharmacies operate across the state, including facilities in Philadelphia, Pittsburgh, Allentown, Harrisburg, and Scranton. These pharmacies can prepare custom doses, alternative delivery forms (such as oral suspensions for patients who cannot swallow standard tablets), or combination formulations that are not commercially available.

What Does Compounded Metformin Cost in Pennsylvania?

Pricing depends on the specific formulation and the pharmacy's program structure. Some telehealth programs offer compounded metformin to enrolled patients at $0 per month as part of a bundled membership that covers prescriber fees, labs, and the medication itself. Standalone compounded metformin from a 503A pharmacy typically runs $15 to $30 per month when billed directly.

Compounded metformin is not covered by most commercial insurance plans because the FDA has not approved a specific compound, and insurers generally require an FDA-approved drug for reimbursement. PA Medicaid does not cover compounded metformin when a commercially available generic exists, per CMS guidance on compound drug coverage.

Legal Boundaries: What 503A Pharmacies Cannot Do

A 503A pharmacy cannot manufacture metformin in bulk without a patient-specific prescription. That activity requires 503B outsourcing facility registration, and no 503B facility currently lists metformin as a bulk compounded product under FDA enforcement discretion. If a pharmacy offers metformin compounded in large pre-made batches without individual prescriptions, that is outside the legal scope of 503A and should prompt caution.

The FDA's guidance on compounding under section 503A of the Federal Food, Drug, and Cosmetic Act is publicly available at FDA.gov [4].

Which Insurance Plans Cover Metformin in Pennsylvania?

Virtually every commercial health insurance plan sold in Pennsylvania covers generic metformin, most at Tier 1 (the lowest cost-sharing level). Pennsylvania is subject to ACA essential health benefits requirements, and diabetes medications are included.

Employer-Sponsored Plans

Large employer plans regulated under ERISA are not technically bound by ACA state mandates, but nearly all major Pennsylvania employers, including those in healthcare, education, and manufacturing, cover generic metformin at $0 to $10 per fill. UPMC Health Plan, Highmark Blue Cross Blue Shield of PA, Aetna, and Cigna all list metformin on their Pennsylvania formularies at the lowest tier as of 2026.

ACA Marketplace Plans in Pennsylvania

Pennsylvania operates its own state exchange, Pennie. All qualified health plans sold on Pennie must cover generic metformin. For plan year 2026, the average Tier 1 copay for a 30-day supply across Pennie plans is $0 to $5 after the deductible, or $0 with a cost-sharing reduction subsidy for enrollees below 250% of the federal poverty level.

Medicare Part D in Pennsylvania

Medicare Part D plans cover metformin universally; it appears on every Part D formulary in the country because CMS requires it as a protected class drug for diabetes. Pennsylvania has 24 stand-alone Part D plans available in 2026. The average copay for generic metformin under PA Part D plans is $0 to $3 per 30-day supply in the initial coverage phase. Enrollees who qualify for the Low-Income Subsidy (LIS) pay $0 [5].

Can I Get a Metformin Prescription via Telehealth in Pennsylvania?

Yes. Pennsylvania law allows licensed physicians, nurse practitioners, and physician assistants to prescribe metformin via synchronous (video) or asynchronous telehealth encounters, provided the prescriber holds a valid Pennsylvania license and completes a clinically appropriate evaluation.

Pennsylvania adopted permanent telehealth prescribing rules following the COVID-19 public health emergency. The PA Medical Practice Act and the PA State Board of Medicine regulations do not require an in-person visit before prescribing metformin, as long as the prescriber can adequately assess the patient's clinical status. A fasting glucose, HbA1c result, and basic metabolic panel (for renal function, since metformin is contraindicated when eGFR falls below 30 mL/min/1.73 m²) are typically reviewed before prescribing.

HealthRX's internal clinical protocol for telehealth metformin initiation in Pennsylvania follows a three-checkpoint model:

1. Eligibility screen: HbA1c 5.7% or above, or confirmed type 2 diabetes diagnosis, plus eGFR 45 mL/min/1.73 m² or above for standard initiation (dose reduction considered for eGFR 30, 44).
2. Contraindication review: Active hepatic impairment, acute or chronic metabolic acidosis, recent iodinated contrast administration within 48 hours, and active alcohol use disorder all require clinical judgment before proceeding.
3. Titration plan: Start at 500 mg once daily with dinner for one week, then 500 mg twice daily with meals. Increase by 500 mg every two weeks as tolerated, targeting 1,500 to 2 to 000 mg per day for most adults. This staged approach reduces the gastrointestinal side effects (nausea, diarrhea) reported in approximately 20 to 30% of patients who begin at higher doses.

Telehealth platforms operating in Pennsylvania include HealthRX, Teladoc, Sesame, and Amazon Clinic, among others. Most offer a metformin consultation for $25 to $75 if the patient is paying cash without insurance.

The Clinical Case for Metformin: Why It Remains First-Line

Metformin has been a first-line agent for type 2 diabetes since the American Diabetes Association and the European Association for the Study of Diabetes issued their joint consensus statement in 2006, and both organizations have reaffirmed that position in every update since [2].

The evidence anchoring this recommendation is substantial. The United Kingdom Prospective Diabetes Study 34 (UKPDS 34, N=1,704 overweight patients with newly diagnosed type 2 diabetes) found that intensive blood-glucose control with metformin reduced all-cause mortality by 36%, diabetes-related death by 42%, and any diabetes-related endpoint by 32% compared with conventional dietary therapy over a median of 10.7 years [6]. No other oral glucose-lowering drug has a mortality outcome dataset of that length or size in a head-to-head trial against diet alone.

The mechanism is primarily hepatic. Metformin activates AMP-activated protein kinase (AMPK) in liver cells, reducing gluconeogenesis and thereby lowering fasting plasma glucose. Secondary mechanisms include modest improvements in peripheral insulin sensitivity and, in some patients, reductions in intestinal glucose absorption.

Metformin and Weight: What the Data Show

Unlike sulfonylureas or insulin, metformin does not cause weight gain. UKPDS 34 showed weight-neutral outcomes in the metformin group versus meaningful weight gain in the sulfonylurea and insulin groups [6]. A 2020 Cochrane review of 18 randomized trials found metformin produced a mean weight change of approximately -1.1 kg compared with placebo over 12 to 52 weeks, a statistically significant but clinically modest effect [7].

For patients also considering GLP-1 receptor agonists (such as semaglutide or tirzepatide), metformin is frequently prescribed concurrently. The ADA 2024 Standards of Care note that metformin may be continued alongside GLP-1 agonist therapy unless renal function declines below threshold [2].

What Are the Cheapest Ways to Get Metformin in Pennsylvania?

Several concrete options exist for Pennsylvania residents who want to minimize their out-of-pocket cost.

Option 1: Walmart $4 Generic Program. Walmart's in-store pharmacy charges $4 for a 30-day supply and $10 for a 90-day supply of metformin immediate-release at all Pennsylvania locations. No membership is required. This is the single lowest cash price available at a major chain statewide.

Option 2: GoodRx or RxSaver at a PA Chain Pharmacy. Presenting a GoodRx coupon at CVS, Walgreens, or Rite Aid can reduce the price to $5 to $9 for a 30-day supply, depending on the specific location and current contracted rates. Prices fluctuate monthly.

Option 3: PA Medicaid (Medical Assistance). For income-eligible residents, Medical Assistance covers metformin at $0 to $3 per fill. Pennsylvanians can check eligibility and apply through COMPASS or through any County Assistance Office.

Option 4: Telehealth Membership Programs. Some telehealth platforms bundle the prescriber visit, lab ordering, and metformin (sometimes compounded) into a monthly membership. Costs range from $0 to $59 per month depending on the plan. This option is most useful for patients who lack a primary care provider or want to avoid scheduling delays.

Option 5: 340B Program at Qualified Pennsylvania Health Centers. Pennsylvania has 112 federally qualified health centers (FQHCs) that participate in the 340B drug pricing program. At these locations, metformin may cost $1 to $3 per month for eligible patients, regardless of insurance status. The HRSA 340B database lists all Pennsylvania 340B sites.

Pennsylvania-Specific Metformin Discount Programs

Beyond standard savings cards, Pennsylvania residents have access to several state-level resources.

The PACE and PACENET programs (Pharmaceutical Assistance Contract for the Elderly) are run by the Pennsylvania Department of Aging and help older Pennsylvanians with drug costs. PACE covers enrollees with annual income at or below $14,500 (single) or $17,700 (married). PACENET extends benefits up to $27,500 (single) or $35,500 (married). Under these programs, metformin copays are typically $6 per 30-day supply for brand-name drugs, and generics like metformin may be covered at a lower flat rate.

The Patient Assistance Foundation programs run by major pharmaceutical manufacturers do not apply to off-patent generics like metformin, but patients who use combination brand-name diabetes medications that contain metformin (such as Synjardy or Janumet) may qualify for manufacturer assistance on those products separately.

Side Effects That May Affect Your Decision

Cost is not the only factor. Roughly 20 to 30% of patients experience gastrointestinal side effects with metformin, most commonly diarrhea, nausea, and abdominal cramping. These effects are dose-dependent and usually resolve within four to eight weeks if the dose is titrated slowly [6].

Long-term metformin use (more than four years) depletes vitamin B12 through reduced ileal absorption. The American Association of Clinical Endocrinology recommends periodic B12 monitoring for patients on chronic metformin therapy [8]. A 2022 analysis of the DPP Outcomes Study found B12 deficiency in 9.8% of long-term metformin users versus 5.4% in the placebo group (P<0.001) [3].

Lactic acidosis is rare but serious. The incidence is approximately 3 cases per 100,000 patient-years in the general metformin-treated population, primarily confined to patients with significant renal impairment, hepatic dysfunction, or acute illness causing hypoperfusion states [9].

Dosing and Administration: Pennsylvania Prescribing Norms

Standard metformin dosing in Pennsylvania clinical practice follows ADA 2024 guidelines:

• Starting dose: 500 mg once or twice daily with meals, or 850 mg once daily.
• Titration: Increase by 500 mg per week or 850 mg every two weeks as tolerated.
• Target dose: 1,500 to 2 to 550 mg per day for most adults with type 2 diabetes.
• Maximum approved dose: 2 to 550 mg per day (immediate-release) or 2 to 000 mg per day (extended-release).
• Renal adjustment: Reduce dose or discontinue when eGFR falls below 45 mL/min/1.73 m²; contraindicated below 30 mL/min/1.73 m².

Taking metformin with food is not optional for gastrointestinal tolerability. It slows absorption and meaningfully reduces nausea rates. The extended-release formulation taken once at dinner produces the lowest peak plasma concentration and is preferred for patients with documented GI intolerance to immediate-release.

For patients initiating via telehealth in Pennsylvania, the prescriber will typically request a comprehensive metabolic panel before the first fill to confirm adequate renal function. Repeat labs at three to six months are standard practice.